Current position : CR1 INSERM RESEARCHER at INSERM UMR-1048
Institute of Metabolic and Cardiovascular Diseases (Director A Parini)
University Paul Sabatier, Toulouse, France.
2002-2004: Post-doctoral fellow, Depatment of Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA. (Director: Stephen Liggett)
1998-2002: Ph.D. , INSERM U446, Laboratory of Cellular and Molecular Cardiology, University Paris-Sud, Châtenay-Malabry, France. Director: Rodolphe Fischmeister.
Heart failure is a major health problem representing about 2% of health costs in developed countries. A powerful predictor for the development of heart failure is the presence of left ventricular hypertrophy. It is believed that progressive deterioration of the hypertrophied left ventricle (LV), which will eventually precipitate in heart failure, is related to progressive loss of cardiac myocytes. Increasing evidences from human and animal models suggest that apoptotic and necrotic cell death could be key modulators in the transition from "compensatory" hypertrophy to heart failure. One of the major challenges for the next years will be the identification of new factors and mechanisms involved in transition from ventricular hypertrophy to cardiac failure. This would be an essential prerequisite for elaborating new preventive or therapeutical strategies of heart failure. In our group, we are studying the role of oxidative stress generated by monoamine oxidases in cardiomyocytes death during transition from ventricular hypertrophy to heart failure and in cardiac senescence. Another axis is developed on the role of serotonin and 5-HT2A receptors during the developement of cardiac hypertrophy.